This past November, I had the opportunity to present our latest research at three international symposia focused on stem cells and aging: in Los Angeles, USA, Singapore, and Hangzhou, China. Each venue showcased a vibrant scientific environment, rich with innovation and passion. I received thoughtful feedback on our recent work, and I engaged in deep conversations with investigators across a spectrum of scientific disciplines. These exchanges, beyond simply sharing data, reminded me how rapidly our field is advancing—and how essential global collaboration is to that progress.

Across these visits, I sensed something very encouraging: while each region has its own distinctive strengths, the ambition to bring stem cell science into the clinic is clearly a shared international priority. Whether through manufacturing innovation, organoid disease modeling, genome and epigenome engineering, or translational neuroscience, researchers everywhere are seeking paths toward real therapeutic impact. This global drive is precisely why the ISSCR exists—and why our annual meeting remains the world’s most important platform for uniting the stem cell community.

In early November, I attended a gene and cell therapy meeting in Los Angeles, USA where the city was still celebrating the L.A. Dodgers’ World Series championship. Amid that energy, I engaged in lively discussions with ISSCR members and leading scientists from around the world. The atmosphere—intense and exhilarating—was reminiscent of a championship game itself. It was clear that advances in stem cell and gene-editing technologies are rapidly accelerating translational research and its societal impact.

The past weeks have been marked by two important actions that together reflect the mission of the ISSCR: to advance stem cell science responsibly and to defend the integrity of biomedical research.

The field of stem cell science is advancing at an extraordinary pace, and yet the question remains: how do we ensure these innovations truly reach patients? To explore this, I spent much of August in the United States—Boston and the San Francisco Bay Area—meeting with leaders across academia (MIT, the Broad Institute, Tufts, Massachusetts General Hospital, McLean Hospital/Harvard Medical School, Gladstone, Stanford), major pharmaceutical companies (Novartis, Sanofi, Eisai), and emerging biotech ventures (Cellino, GC Therapeutics, Shinobi Therapeutics). Through lectures and exchanges, I gained a clearer view of the progress being made, the obstacles still ahead, and the breakthroughs most urgently needed. These conversations reminded me that the ISSCR’s most vital role is to serve as a trusted platform where such knowledge can be shared globally and effectively.

As I begin my term as President of the ISSCR, I am honored to serve this dynamic and forward-looking global community of stem cell researchers, clinicians, and innovators. This year marks the final phase of our 2022–2025 strategic framework, which has guided our efforts around four central goals.

In the year ahead, I intend not only to complete these goals but also to critically reflect on the progress we’ve made. What worked well? What challenges remain? And how can these insights guide our vision for the next strategic cycle? These four pillars remain deeply relevant and will continue to shape the ISSCR’s direction in the coming years.